These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

275 related articles for article (PubMed ID: 22457688)

  • 21. Effect of homocysteinylation on human high-density lipoproteins: a correlation with paraoxonase activity.
    Ferretti G; Bacchetti T; Marotti E; Curatola G
    Metabolism; 2003 Feb; 52(2):146-51. PubMed ID: 12601623
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Inactivation of the paraoxonase 1 gene affects the expression of mouse brain proteins involved in neurodegeneration.
    Suszyńska-Zajczyk J; Luczak M; Marczak L; Jakubowski H
    J Alzheimers Dis; 2014; 42(1):247-60. PubMed ID: 24844689
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The Structure and Function of Paraoxonase-1 and Its Comparison to Paraoxonase-2 and -3.
    Taler-Verčič A; Goličnik M; Bavec A
    Molecules; 2020 Dec; 25(24):. PubMed ID: 33348669
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The role of paraoxonase 1 in the detoxification of homocysteine thiolactone.
    Jakubowski H
    Adv Exp Med Biol; 2010; 660():113-27. PubMed ID: 20221875
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Decreased paraoxonase 1 (PON1) lactonase activity in hemodialyzed and renal transplanted patients. A novel cardiovascular biomarker in end-stage renal disease.
    Sztanek F; Seres I; Harangi M; Lőcsey L; Padra J; Paragh GJ; Asztalos L; Paragh G
    Nephrol Dial Transplant; 2012 Jul; 27(7):2866-72. PubMed ID: 22247228
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Impact of the 24-h ultramarathon race on homocysteine, oxidized low-density lipoprotein, and paraoxonase 1 levels in professional runners.
    Benedetti S; Catalani S; Peda F; Luchetti F; Citarella R; Battistelli S
    PLoS One; 2018; 13(2):e0192392. PubMed ID: 29394290
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Cladribine Treatment Improved Homocysteine Metabolism and Increased Total Serum Antioxidant Activity in Secondary Progressive Multiple Sclerosis Patients.
    Jamroz-Wiśniewska A; Bełtowski J; Wójcicka G; Bartosik-Psujek H; Rejdak K
    Oxid Med Cell Longev; 2020; 2020():1654754. PubMed ID: 32256946
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Effect of homocysteinylation on high density lipoprotein physico-chemical properties.
    Ferretti G; Bacchetti T; Masciangelo S; Bicchiega V
    Chem Phys Lipids; 2010 Feb; 163(2):228-35. PubMed ID: 19962972
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Paraoxonases-1, -2 and -3: What are their functions?
    Furlong CE; Marsillach J; Jarvik GP; Costa LG
    Chem Biol Interact; 2016 Nov; 259(Pt B):51-62. PubMed ID: 27238723
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Protein N-homocysteinylation: implications for atherosclerosis.
    Jakubowski H
    Biomed Pharmacother; 2001 Oct; 55(8):443-7. PubMed ID: 11686577
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Paraoxonase genotypes, lipoprotein lipase activity, and HDL.
    Nevin DN; Zambon A; Furlong CE; Richter RJ; Humbert R; Hokanson JE; Brunzell JD
    Arterioscler Thromb Vasc Biol; 1996 Oct; 16(10):1243-9. PubMed ID: 8857920
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Effects of antiretroviral treatment on paraoxonase 1 (PON1) activity in rats.
    Pastryk JE; Rusek M; Bełtowski J
    Chem Biol Interact; 2016 Nov; 259(Pt B):407-412. PubMed ID: 27378623
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Paraoxonase, arylesterase and lactonase activities of paraoxonase-1 (PON1) in obese and severely obese women.
    Cervellati C; Bonaccorsi G; Trentini A; Valacchi G; Sanz JM; Squerzanti M; Spagnolo M; Massari L; Crivellari I; Greco P; Parladori R; Passaro A; Ricci G
    Scand J Clin Lab Invest; 2018; 78(1-2):18-24. PubMed ID: 29168398
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Effect of oxidative stress on antioxidant enzyme activities, homocysteine and lipoproteins in chronic kidney disease.
    Atamer A; Kocyigit Y; Ecder SA; Selek S; Ilhan N; Ecder T; Atamer Y
    J Nephrol; 2008; 21(6):924-30. PubMed ID: 19034878
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Paraoxonase activity in Greek migrants and Anglo-Celtic persons in the Melbourne Collaborative Cohort Study: relationship to dietary markers.
    Lee CT; Rowley K; Jenkins AJ; O'Dea K; Itsiopoulos C; Stoney RM; Su Q; Giles GG; Best JD
    Eur J Nutr; 2005 Jun; 44(4):223-30. PubMed ID: 15309416
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The effect of HDL-bound and free PON1 on copper-induced LDL oxidation.
    Bayrak A; Bayrak T; Bodur E; Kılınç K; Demirpençe E
    Chem Biol Interact; 2016 Sep; 257():141-6. PubMed ID: 27510818
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Paraoxonase 1 activity in patients with chronic obstructive pulmonary disease.
    Rumora L; Rajković MG; Kopčinović LM; Pancirov D; Čepelak I; Grubišić TŽ
    COPD; 2014 Sep; 11(5):539-45. PubMed ID: 24831724
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Hypochlorous acid and low serum paraoxonase activity in haemodialysis patients: an in vitro study.
    Sutherland WH; de Jong SA; Walker RJ
    Nephrol Dial Transplant; 2004 Jan; 19(1):75-82. PubMed ID: 14671042
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Paraoxonase, a cardioprotective enzyme: continuing issues.
    Getz GS; Reardon CA
    Curr Opin Lipidol; 2004 Jun; 15(3):261-7. PubMed ID: 15166781
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Species differences in paraoxonase mediated hydrolysis of several organophosphorus insecticide metabolites.
    Carr RL; Dail MB; Chambers HW; Chambers JE
    J Toxicol; 2015; 2015():470189. PubMed ID: 25784934
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.